NCT00490061 - Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2013

Study Completion Date

June 30, 2016

Conditions

Head and Neck CancerCarcinoma, Squamous CellHead and Neck Cancers

Interventions

DRUG

Lapatinib

1500 mg po daily orally

PROCEDURE

Radiotherapy (radiation)

Standard of Care

DEVICE

G.E. Healthcare 1.5T MR, systems revision 12.0 M5

Standard of Care, used to deliver IMRT

DEVICE

DCE-MRI

A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.

Trial Locations (5)

Beth Israel, New York

Duke University, Durham

University of Florida Shands Cancer Center, Gainsville

University of Wisconsin Cancer Center, Madison

Stanford University School of Medicine, Stanford